Friday, December 10, 2021
Rapid Dose Therapeutics Corp., a Canadian biotechnology company revolutionizing drug delivery through innovation, entered into an agreement on Friday, November 26, 2021 with Oakland Health Limited (“Oakland Health” operating as “RD Therapeutics”) to supply QuickStrip™ products to the United Kingdom and the European Union.
“This strategic partnership supports our business plan of rapid global expansion, bringing our novel QuickStrip™ technology and nutraceutical products into the United Kingdom, with further expansion plans throughout the European Union,” said Mark Upsdell, CEO Rapid Dose Therapeutics. “It is as a result of our strategic partnerships with leading organizations such as RD Therapeutics that we will achieve broader awareness of our novel delivery technology, as it becomes more widely used, including as an oral delivery system for vaccines.”
RD Therapeutics is well positioned to maximize sales in these geographies, with their strong relationships throughout the UK and EU in both pharmacy and retail chains, critical for broad education and uptake of QuickStrip™ products in these markets.
“We are very pleased to have been selected by Rapid Dose Therapeutics to bring their innovative products to the UK and EU marketplaces,” said Ailene Thiel, CEO, RD Therapeutics. “This novel technology will be welcomed in these markets as a truly innovative delivery mechanism, initially for nutraceuticals, with expansion into pharmaceuticals and vaccines to follow. We are looking forward to operating as RDT’s UK and European supply partners and will support the marketing and sales of these outstanding products with scientific rigour and our in-depth knowledge of the markets we serve.”
RD Therapeutics placed an initial product order on Friday, December 3, 2021, including RDT and white label branded products in the lifestyle, health and wellness sectors, for delivery in Q1 2022.